TABLE 8Patient characteristics

Study IDName of interventionnAge (range), yearsMale, n (%)Severity, n (%)Loss to follow-up
ReasonTotal n (%)Final nITT
RCTs
Golden 198041,44Slow therapy22NRNRCutaneous signs only: 7/64 (10.9)

Urticaria: 44/64 (68.8)

Dizziness or hypotension: 43/64 (67.2)

Throat swelling or hoarseness: 32/64 (50.0)

Dyspnoea: 31/64 (48.4)

Loss of consciousness: 19/64 (29.7)

Wheezing: 5/64 (7.8)
2 no SC: not reached maintenance due to systemic reaction and local reaction to VIT

1 no SC: not reached maintenance as 2-month interruption in therapy

1 no SC because of cardiac status

2 no SC because of illness or cardiac status

1 no SC: only treated with Polistes wasp venom

1 no SC: anti-venom IgE was in doubt at the time
3 (13.6)19No
Step therapy201 (5.0)19No
Rush therapy224 (18.2)18No
Mosbech 198645Pharmalgen1046 (21–62)NRUrticaria/angioedema: 8/10 (80%)

Respiratory symptoms: 6/10 (60%)

CNS symptoms: 5/10 (50%)
1 immunotherapy with bee venom

1 local and systemic side effects

1 other disease

1 lack of time

3 no SC: reason unclear
7 (70.0)3No
Alutard1241 (29–79)NRUrticaria/angioedema: 11/12 (91.7%)

Respiratory symptoms: 7/12 (58.3%)

CNS symptoms: 9/12 (75%)
1 psychic reactions

1 other disease

1 unknown

1 emigration

1 no SC: reason unclear
5 (41.7)7No
Aquagen1040 (24–60)NRUrticaria/angioedema: 7/10 (70)

Respiratory symptoms: 3/10 (30)

CNS symptoms: 7/10 (70)
1 no SC: reason unclear1 (10.0)9No
Müller 198746,47HBV1734.5 (17–57)15 (88.2)Urticaria/angioedema: 3/17 (17.6)

Respiratory: 10/17 (58.8)

Shock: 4/17 (23.5)
2 side effects

1 went abroad
3 (17.6)14No
Monomethoxy polyethylene glycol-coupled HBV1734.6 (17–70)13 (76.5)Urticaria/angioedema: 5/17 (29.4)

Respiratory: 9/17 (52.9)

Shock: 3/17 (17.6)
None0 (0)17No
Quercia 200148Pharmalgen: cluster2046.35 (28–76)16/20 (80)Grade 1: 0 (0.0)

Grade 2: 10 (50.0)

Grade 3: 5 (25.0)

Grade 4: 5 (25.0)
NA0 (0)20NA
Pharmalgen: rush2048.5 (18–73)16/20 (80)Grade 1: 1 (5.0)

Grade 2: 5 (25.0)

Grade 3: 11 (55.0)

Grade 4: 3 (15.0)
NA0 (0.0)20NA
Depot cluster1541.47 (18–68)13/15 (86.7)Grade 1: 1 (7.7)

Grade 2: 4 (30.8)

Grade 3: 6 (46.2)

Grade 4: 4 (30.8)
NA0 (0.0)15NA
Non-RCTs
Cadario 200440Aqueous induction and aqueous maintenance1842.6 (19–69)15 (83.3)Grade 2: 9 (50.0)

Grade 3: 0 (0.0)

Grade 4: 9 (50.0)
NA0 (0.0)18NA
Depot induction and depot maintenance2739.0 (15–68)19 (70.4)Grade 2: 5 (18.5)

Grade 3: 9 (33.3)

Grade 4: 13 (48.1)
NA0 (0.0)27NA
Golden 19814350 μg maintenance23NR14 (60.9)Cutaneous signs only: 10/65 (15.4)

Urticaria: 50/65 (77)
4 not available for SC4 (17.4)19No
100 μg maintenance442213 (59.1)Dizziness or hypotension: 41/65 (63.1)

Throat swelling or hoarseness: 26/65 (40)

Dyspnoea/wheezing: 27/65 (41.5)

Loss of consciousness: 22/65 (33.8)
2 no SC: illness or cardiac status

1 no SC: only treated with Polistes wasp venom

1 no SC: anti-venom IgG was in doubt at the time
4 (18.2)18No
100 μg maintenance282013 (65.0)1 no SC: could not tolerate maintenance dose1 (5.0)19No
Golden 1981424-weekly maintenance aNRNRNRNR1 not available for SC

None others stated
NR42No
6-weekly maintenance30NRNRNR1 not available for SC1 (3.3)29No
4-weekly maintenance bNRNRNRNR1 not available for SC

None others stated
NR56No
Patriarca 200832Ultra-rush SCIT2035 (±14)16/20 (80)Grade 1: 1 (5)

Grade 2: 9 (45)

Grade 3: 4 (20)

Grade 4: 6 (30)
NA0 (0.0)20No
Ultra-rush SLIT2138 (±16)15/21 (71.4)Grade 1: 3 (14.3)

Grade 2: 11 (52.4)

Grade 3: 3 (14.3)

Grade 4: 4 (19.0)
2 lack of compliance

2 continued but did not have other outcomes measured
4 (19.0)17No
Thumheer 198349Conventional2136.3 (±15.4) (6–69)12/21 (57.1)Grade 1: 2 (9.5)

Grade 2: 3 (14.3)

Grade 3: 11 (52.4)

Grade 4: 5 (23.8)
1 pregnancy

1 treatment failure
2/42 (4.8)40No
Rush2136.1 (±19.3) (11–70)13/21 (61.9)Grade 1: 1 (4.8)

Grade 2: 5 (23.8)

Grade 3: 9 (42.9)

Grade 4: 6 (28.6)
NA

CNS, central nervous system; HBV, honey bee venom; NA, not applicable; NR, Not reported; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy.

From: 3, Assessment of clinical effectiveness

Cover of A Systematic Review of the Clinical Effectiveness and Cost-Effectiveness of Pharmalgen® for the Treatment of Bee and Wasp Venom Allergy
A Systematic Review of the Clinical Effectiveness and Cost-Effectiveness of Pharmalgen® for the Treatment of Bee and Wasp Venom Allergy.
Health Technology Assessment, No. 16.12.
Hockenhull J, Elremeli M, Cherry MG, et al.
Southampton (UK): NIHR Journals Library; 2012 Mar.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.